Company Filing History:
Years Active: 2021-2023
Title: Yanli Dai: Innovator in Pharmaceutical Crystal Forms
Introduction
Yanli Dai is a notable inventor based in Zhejiang, China, recognized for his contributions to pharmaceuticals, particularly in the development of innovative crystal forms of tipifarnib. With a total of two patents to his name, Dai’s work addresses significant challenges within the treatment of abnormal cell growth diseases.
Latest Patents
Yanli Dai's latest patents include two inventions related to novel crystal forms of tipifarnib. The first patent discusses the advantages of these crystal forms over prior art, highlighting improvements in crystallinity, hygroscopicity, morphology, form stability, and chemical stability. Furthermore, this patent outlines methods for preparing these crystal forms, as well as their pharmaceutical compositions and applications in the treatment and prevention of diseases characterized by abnormal cell growth. The second patent reiterates the same novel attributes of the crystal forms, emphasizing their potential in pharmaceutical applications and reinforcing Dai’s innovative contributions to the field.
Career Highlights
Dai is currently affiliated with Hangzhou Solipharma Co., Ltd., where he has been instrumental in advancing research and development in pharmaceutical sciences. His background in chemistry and drug formulation enables him to lead pioneering projects that push the boundaries of conventional pharmaceutical practices. His work is poised to facilitate better treatment options for patients, making significant inroads in the medical industry.
Collaborations
Throughout his career, Yanli Dai has collaborated with esteemed professionals in the field, notably Xiaohong Sheng and Xiaoxia Sheng. These partnerships have facilitated a shared exchange of ideas and expertise, further enriching his research contributions and leading to impactful innovations in pharmaceuticals.
Conclusion
Yanli Dai stands out as a significant figure in the realm of pharmaceutical inventions, particularly with his advancements in the crystal forms of tipifarnib. His dedication to innovation not only reflects his individual expertise but also his commitment to enhancing therapeutic solutions for critical health challenges. As he continues to work with top-tier colleagues at Hangzhou Solipharma Co., Ltd., the future looks promising for further developments in his field of expertise.